Extended Follow-up of Treatment of Prednisone Plus Cyclop... | NCT03218852 | Trialant

Extended Follow-up of Treatment of Prednisone Plus Cyclop... | NCT03218852 | Trialant

Arms/Interventions Module

Arm Groups

Label	Type	Description	Intervention Names
prednisone and cyclophosphamide	Experimental	prednisone(0.5mg/kg/day6 months) cyclophosphamide(1g intravenous use,per 1 month6months); supportive care,including ACE-I or ARBs and blood pressure control	Drug: prednisone and cyclophosphamide
prednisone alone	Experimental	prednisone(0.5mg/kg/day*6months); supportive care,including ACE-I or ARBs and blood pressure control	Drug: prednisone alone

Interventions

Name	Type	Description	Arm Group Labels	Other Names
prednisone and cyclophosphamide	Drug	Prednisone and cyclophosphamide are both administered to participants in this group.	prednisone and cyclophosphamide

Outcomes Module

Primary Outcomes

Measure	Description	Time Frame
the changes of kidney function or death	addition of 2-year-follow up to the ClinicalTrials.gov ID: NCT01758120;Time Frame:4 years and 5 years after the initiation of treatment the changes of estimated glomerular filtration rate (eGFR) or a combination of reaching end-stage renal disease (ESRD) or doubling of serum Creatinine or death	a total of 5 years of followup (addition of 2-year-follow up to the ClinicalTrial of NCT01758120)

Secondary Outcomes

Measure	Description	Time Frame
the changes of proteinuria	addition of 2-year-follow up to the ClinicalTrials.gov ID: NCT01758120;Time Frame:4 years and 5 years after the initiation of treatment the changes of proteinuria	a total of 5 years of followup (addition of 2-year-follow up to the ClinicalTrial of NCT01758120)
Number of Participants with Adverse Events

Condition Browse Module

Intervention Browse Module